<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AVANDIA- rosiglitazone maleateÂ tablet, film coatedÂ </strong><br><strong>AVANDIAÂ 2MG- rosiglitazone maleateÂ tablet, film coatedÂ </strong><br><strong>AVANDIAÂ 4MG- rosiglitazone maleateÂ tablet, film coatedÂ </strong><br><strong>AVANDIAÂ 8MG- rosiglitazone maleateÂ tablet, film coatedÂ </strong><br>GlaxoSmithKline LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AVANDIA safely and effectively. See full prescribing information for AVANDIA.<br>AVANDIA (rosiglitazone maleate) tablets<br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>Â </dt>
<dd><span class="Bold">â—?	Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients (<a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>	). After initiation of AVANDIA, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of AVANDIA must be considered.</span></dd>
<dt>Â </dt>
<dd><span class="Bold">â—?	AVANDIA is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation of AVANDIA in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a">4</a>	, <a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>	)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="91%">
<col width="9%">
<tbody class="Headless">
<tr>
<td class="Toprule"><p class="Highlighta">Boxed Warning, AVANDIA-Rosiglitazone Medicines Access Program removal </p></td>
<td class="Toprule"><p class="Highlighta">05/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Indications and Usage, patient population restrictions removal (<a href="#i4i_indications_id_20e47e1f-c1be-4490-aea1-200ebe0d9b7e">1</a>)  </p></td>
<td><p class="Highlighta">05/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Contraindications (<a href="#i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a">4</a>) </p></td>
<td><p class="Highlighta">05/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> (<a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>) </p></td>
<td><p class="Highlighta">05/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Warnings and Precautions, Major Adverse Cardiovascular Events (<a href="#ID_e6c636b2-6b54-41db-a3dc-f866aad2ec36">5.2</a>) </p></td>
<td><p class="Highlighta">05/2014 </p></td>
</tr>
<tr>
<td class="Botrule"><p class="Highlighta">Warnings and Precautions, Rosiglitazone REMS (Risk Evaluation and Mitigation Strategy) Program removal (formerly 5.3) </p></td>
<td class="Botrule"><p class="Highlighta">05/2014 </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>Â </dt>
<dd><span class="Bold">â—?	Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients (<a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>	). After initiation of AVANDIA, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of AVANDIA must be considered.</span></dd>
<dt>Â </dt>
<dd><span class="Bold">â—?	AVANDIA is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation of AVANDIA in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a">4</a>	, <a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>	)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">AVANDIA is a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (<a href="#ID_7986a2ec-839a-41d1-a632-185a07abc8ab">1</a>) </p>
<p class="Highlighta">Important Limitations of Use:  </p>
<dl>
<dt>â€¢</dt>
<dd>AVANDIA should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_indications_id_20e47e1f-c1be-4490-aea1-200ebe0d9b7e">1</a>)</dd>
<dt>â€¢</dt>
<dd>Coadministration of AVANDIA and insulin is not recommended. (<a href="#i4i_indications_id_20e47e1f-c1be-4490-aea1-200ebe0d9b7e">1</a>, <a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>, <a href="#ID_e6c636b2-6b54-41db-a3dc-f866aad2ec36">5.2</a>) </dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily. (<a href="#i4i_dosage_admin_id_f4f6170b-ab01-48d3-b3b5-da144b157f6c">2</a>)</dd>
<dt>â€¢</dt>
<dd>Dose increases should be accompanied by careful monitoring for adverse events related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (<a href="#i4i_dosage_admin_id_f4f6170b-ab01-48d3-b3b5-da144b157f6c">2</a>)</dd>
<dt>â€¢</dt>
<dd>Do not initiate AVANDIA if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels. (<a href="#ID_ccdcc997-9eb1-4bb2-8f52-3e1b762342c6">2.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Pentagonal, film-coated tablets in the following strengths: 2Â mg, 4Â mg, and 8Â mg (<a href="#i4i_dosage_form_strength_id_1e4ecdc1-a45f-4d4e-91e2-fd6a658fb2fc">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Initiation in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a">4</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to rosiglitazone or any of the productâ€™s ingredients. (<a href="#i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, which may exacerbate or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, may occur. Combination use with insulin and use in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> NYHA Class I and II may increase risk of other cardiovascular effects. (<a href="#ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Meta-analysis of 52 mostly short-term trials suggested a potential risk of ischemic cardiovascular (CV) events relative to placebo, not confirmed in a long-term CV outcome trial versus metformin or sulfonylurea. (<a href="#ID_e6c636b2-6b54-41db-a3dc-f866aad2ec36">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>Dose-related <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<a href="#_Ref">5.3</a>), <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (<a href="#ID_e7348c71-fd0c-48c2-bf45-10cecd499c84">5.4</a>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (<a href="#ID_e4c5cad3-b747-4fd8-95a1-4c14b0e15b21">5.8</a>) may occur.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported. (<a href="#ID_e8c882d3-e208-4e88-956e-3a5e706ecbd3">5.6</a>)</dd>
<dt>â€¢</dt>
<dd>Increased incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. (<a href="#ID_94000f3a-f395-4d73-8e9f-124f76d50461">5.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions (&gt;5%) reported in clinical trials without regard to causality were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, injury, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#ID_5518f874-7f58-454e-a001-e8ab86bc6eeb">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <a href="#_Ref">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. (<a href="#ID_1ccab237-cb94-4563-9c0d-4c45e9576e66">7.1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: No adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. (<a href="#ID_db48ce6c-2643-4208-baa6-eaf72a476077">8.1</a>)</dd>
<dt>â€¢</dt>
<dd>Nursing Mothers: Discontinue drug or nursing. (<a href="#ID_68254538-5fe5-44f7-9bf0-72658c57fb6b">8.3</a>)</dd>
<dt>â€¢</dt>
<dd>Safety and effectiveness in children younger than 18 years have not been established. (<a href="#ID_7c24928b-262f-4fca-af12-5230016441ab">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Specific Patient Populations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Major Adverse Cardiovascular Events </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Hematologic Effects</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and Blood Glucose Control</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Ovulation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Laboratory Abnormalities</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP2C8 Inhibitors and Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Drug-drug Interactions</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Monotherapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination With Metformin or Sulfonylurea</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Combination With Sulfonylurea Plus Metformin</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_7986a2ec-839a-41d1-a632-185a07abc8ab"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<dl>
<dt>Â </dt>
<dd>â—?<span class="Bold">	Thiazolidinediones, including rosiglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients <span class="Italics">	[see Warnings and Precautions (5.1)]</span>	. After initiation of AVANDIA<span class="Sup">	Â®</span>	, and after dose increases, observe patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (including excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of AVANDIA must be considered.</span>
</dd>
<dt>Â </dt>
<dd><span class="Bold">â—?	AVANDIA is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Initiation of AVANDIA in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. <span class="Italics">[See Contraindications (4), Warnings and Precautions (5.1).]</span></span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_20e47e1f-c1be-4490-aea1-200ebe0d9b7e"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">AVANDIA is a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p><span class="Bold">Important Limitations of Use:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</dd>
<dt>â€¢</dt>
<dd>The coadministration of AVANDIA and insulin is not recommended <span class="Italics">[see Warnings and Precautions (5.1)]</span>. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f4f6170b-ab01-48d3-b3b5-da144b157f6c"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">AVANDIA may be administered at a starting dose of 4Â mg either as a single daily dose or in 2 divided doses. For patients who respond inadequately following 8 to 12Â weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to 8Â mg daily. Increases in the dose of AVANDIA should be accompanied by careful monitoring for adverse events related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>. AVANDIA may be taken with or without food.</p>
<p>The total daily dose of AVANDIA should not exceed 8Â mg.</p>
<p>Patients receiving AVANDIA in combination with other hypoglycemic agents may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and a reduction in the dose of the concomitant agent may be necessary.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ccdcc997-9eb1-4bb2-8f52-3e1b762342c6"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Specific Patient Populations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> No dosage adjustment is necessary when AVANDIA is used as monotherapy in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Since metformin is contraindicated in such patients, concomitant administration of metformin and AVANDIA is also contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Liver enzymes should be measured prior to initiating treatment with AVANDIA. Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal at start of therapy). After initiation of AVANDIA, liver enzymes should be monitored periodically per the clinical judgment of the healthcare professional. <span class="Italics">[See Warnings and Precautions (5.5), Clinical Pharmacology (12.3).]</span></p>
<p><span class="Underline">Pediatric:</span> Data are insufficient to recommend pediatric use of AVANDIA <span class="Italics">[see Use in Specific Populations (8.4)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_1e4ecdc1-a45f-4d4e-91e2-fd6a658fb2fc"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Pentagonal film-coated TILTAB<span class="Sup">Â®</span> tablet contains rosiglitazone as the maleate as follows:</p>
<dl>
<dt>â€¢</dt>
<dd>2 mg â€“ pink, debossed with GSK on one side and 2 on the other</dd>
<dt>â€¢</dt>
<dd>4 mg â€“ orange, debossed with GSK on one side and 4 on the other</dd>
<dt>â€¢</dt>
<dd>8 mg â€“ red-brown, debossed with GSK on one side and 8 on the other</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_909f8a95-085a-456f-8442-5fe1449f130a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>â€¢</dt>
<dd>Initiation of AVANDIA in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated <span class="Italics">[see Boxed Warning]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="XmChange">Use in patients with a history of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to rosiglitazone or any of the productâ€™s ingredients.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_401c5f79-bd17-4ac6-b87c-436f49b8cba9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8ba36b52-85fb-44cc-8d7e-157ab329ddd8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">AVANDIA, like other thiazolidinediones, alone or in combination with other antidiabetic agents, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which may exacerbate or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If these signs and symptoms develop, the <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of rosiglitazone must be considered <span class="Italics">[see Boxed Warning]</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) NYHA Class I and II treated with AVANDIA have an increased risk of cardiovascular events. A 52-week, double-blind, placebo-controlled, echocardiographic trial was conducted in 224 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and NYHA ClassÂ I or II CHF (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤45%) on background antidiabetic and CHF therapy. An independent committee conducted a blinded evaluation of fluid-related events (including <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>) and cardiovascular hospitalizations according to predefined criteria (adjudication). Separate from the adjudication, other cardiovascular adverse events were reported by investigators. Although no treatment difference in change from baseline of <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fractions</span> was observed, more cardiovascular adverse events were observed following treatment with AVANDIA compared with placebo during the 52-week trial. (See Table 1.)</p>
<a name="_RefID0EDZAG"></a><table width="100%">
<caption><span>Table 1. Emergent Cardiovascular Adverse Events in Patients With <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (NYHA Class I and II) Treated With AVANDIA or Placebo (in Addition to Background Antidiabetic and CHF Therapy) </span></caption>
<col width="67%">
<col width="18%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Events</span></p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">N = 110</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N = 114</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Adjudicated</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (5%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CHF worsening</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7 (6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	â€“ with overnight hospitalization</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (5%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	â€“ without overnight hospitalization</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (2%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0 (0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">New or worsening <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">28 (25%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">New or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">29 (26%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19 (17%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Increases in CHF medication</p></td>
<td class="Botrule Rrule" align="center"><p class="First">36 (33%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20 (18%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cardiovascular hospitalization<span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">21 (19%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15 (13%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Investigator-reported, non-adjudicated</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ischemic adverse events </p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	â€“ <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (5%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	â€“ Angina</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">6 (5%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (3%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â Includes hospitalization for any cardiovascular reason.</p>
<p style="border-left:1px solid;"><span class="XmChange">In a long-term, cardiovascular outcome trial (RECORD) in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see Adverse Reactions (6.1)]</span>, the incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> was higher in patients treated with AVANDIA [2.7% (61/2,220) compared with active control 1.3% (29/2,227), HR 2.10 (95% CI: 1.35, 3.27)].</span></p>
<p>Initiation of AVANDIA in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. AVANDIA is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="Italics">[See Boxed Warning.]</span></p>
<p>Patients experiencing <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndromes</span> have not been studied in controlled clinical trials. In view of the potential for development of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in patients having an acute coronary event, initiation of AVANDIA is not recommended for patients experiencing an acute coronary event, and discontinuation of AVANDIA during this acute phase should be considered.</p>
<p>Patients with NYHA Class III and IV cardiac status (with or without CHF) have not been studied in controlled clinical trials. AVANDIA is not recommended in patients with NYHA Class III and IV cardiac status.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> During Coadministration of AVANDIA With Insulin:</span> In trials in which AVANDIA was added to insulin, AVANDIA increased the risk of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Coadministration of AVANDIA and insulin is not recommended. <span class="Italics">[See Indications and Usage (1), Warnings and Precautions (5.2).]</span></p>
<p>In 7 controlled, randomized, double-blind trials which had durations from 16 to 26Â weeks and which were included in a meta-analysis <span class="Italics">[see Warnings and Precautions (5.2)]</span>, patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus were randomized to coadministration of AVANDIA and insulin (NÂ =Â 1,018) or insulin (NÂ =Â 815). In these 7 trials, AVANDIA was added to insulin. These trials included patients with long-standing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (median duration of 12 years) and a high prevalence of pre-existing medical conditions, including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, vascular disease, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The total number of patients with emergent <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> was 23 (2.3%) and 8 (1.0%) in the group receiving AVANDIA plus insulin and the insulin group, respectively.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Observational Studies of Elderly Diabetic Patients Comparing AVANDIA to Pioglitazone:</span> Three observational studies in elderly diabetic patients (age 65 years and older) found that AVANDIA statistically significantly increased the risk of hospitalized <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> compared to use of pioglitazone. One other observational study in patients with a mean age of 54 years, which also included an analysis in a subpopulation of patients &gt;65 years of age, found no statistically significant increase in emergency department visits or hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in patients treated with AVANDIA compared to pioglitazone in the older subgroup.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e6c636b2-6b54-41db-a3dc-f866aad2ec36"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Major Adverse Cardiovascular Events </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Data from long-term, prospective, randomized, controlled clinical trials of AVANDIA versus metformin or sulfonylureas, particularly a cardiovascular outcome trial (RECORD), observed no difference in overall mortality or in major adverse cardiovascular events (MACE) and its components. A meta-analysis of mostly short-term trials suggested an increased risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> with AVANDIA compared with placebo.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Cardiovascular Events in Large, Long-term, Prospective, Randomized, Controlled Trials of AVANDIA:</span> RECORD, a prospectively designed cardiovascular outcome trial (mean follow-up 5.5 years; 4,447 patients), compared the addition of AVANDIA to metformin or a sulfonylurea (NÂ =Â 2,220) with a control group of metformin plus sulfonylurea (NÂ =Â 2,227) in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see Adverse Reactions (6.1)]</span>. Non-inferiority was demonstrated for the primary endpoint, cardiovascular hospitalization or cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, for AVANDIA compared with control [HR 0.99 (95% CI: 0.85, 1.16)] demonstrating no overall increased risk in cardiovascular morbidity or mortality. The hazard ratios for total mortality and MACE were consistent with the primary endpoint and the 95% CI similarly excluded a 20% increase in risk for AVANDIA. The hazard ratios for the components of MACE were 0.72 (95% CI: 0.49, 1.06) for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, 1.14 (95% CI: 0.80, 1.63) for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and 0.84 (95% CI: 0.59, 1.18) for cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">The results of RECORD are consistent with the findings of 2 earlier long-term, prospective, randomized, controlled clinical trials (each trial &gt;3 yearsâ€™ duration; total of 9,620 patients) (see Figure 1). In patients with impaired glucose tolerance (DREAM trial), although the incidence of cardiovascular events was higher among subjects who were randomized to AVANDIA in combination with ramipril than among subjects randomized to ramipril alone, no statistically significant differences were observed for MACE and its components between AVANDIA and placebo. In type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients who were initiating oral agent monotherapy (ADOPT trial), no statistically significant differences were observed for MACE and its components between AVANDIA and metformin or a sulfonylurea.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Figure 1. Hazard Ratios for the Risk of MACE, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Total Mortality With AVANDIA Compared With a Control Group in Long-term Trials</span></span></p>
<div class="Figure">
<a name="id7961005"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-01.jpg">
</div>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Cardiovascular Events in a Group of 52 Clinical Trials:</span> In a meta-analysis of 52 double-blind, randomized, controlled clinical trials designed to assess glucose-lowering efficacy in type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (mean duration 6 months), a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> with AVANDIA versus pooled comparators was observed [0.4% versus 0.3%; OR 1.8, (95% CI: 1.03, 3.25)]. A statistically non-significant increased risk of MACE was observed with AVANDIA versus pooled comparators (OR 1.44, 95% CI: 0.95, 2.20). In the placebo-controlled trials, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [0.4% versus 0.2%, OR 2.23 (95% CI: 1.14, 4.64)] and statistically non-significant increased risk of MACE [0.7% versus 0.5%, OR 1.53 (95% CI: 0.94, 2.54)] with AVANDIA were observed. In the active-controlled trials, there was no increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or MACE.</span></p>
<p><span class="Underline">Mortality in Observational Studies of AVANDIA Compared to Pioglitazone:</span> Three observational studies in elderly diabetic patients (age 65 years and older) found that AVANDIA statistically significantly increased the risk of all-cause mortality compared to use of pioglitazone. One observational study in patients with a mean age of 54 years found no difference in all-cause mortality between patients treated with AVANDIA compared to pioglitazone and reported similar results in the subpopulation of patients &gt;65 years of age. One additional small, prospective, observational study found no statistically significant differences for CV mortality and all-cause mortality in patients treated with AVANDIA compared to pioglitazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e7348c71-fd0c-48c2-bf45-10cecd499c84"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">AVANDIA should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. In a clinical trial in healthy volunteers who received 8Â mg of AVANDIA once daily for 8Â weeks, there was a statistically significant increase in median plasma volume compared with placebo.</p>
<p>Since thiazolidinediones, including rosiglitazone, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, AVANDIA should be used with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1), Patient Counseling Information (17)]</span>.</p>
<p>In controlled clinical trials of patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, mild to moderate <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in patients treated with AVANDIA, and may be dose related. Patients with ongoing <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> were more likely to have adverse events associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> if started on combination therapy with insulin and AVANDIA <span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_486d5543-a4de-44f7-892a-17687f87da3d"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">Dose-related <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was seen with AVANDIA alone and in combination with other hypoglycemic agents (Table 2). The mechanism of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> is unclear but probably involves a combination of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and fat accumulation.</p>
<p>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see Boxed Warning]</span>.</p>
<a name="_RefID0ELWBG"></a><table width="100%">
<caption><span>Table 2. Weight Changes (kg) From Baseline at Endpoint During Clinical Trials</span></caption>
<col width="19%">
<col width="11%">
<col width="19%">
<col width="17%">
<col width="17%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Monotherapy</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Duration</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Control Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">4 mg</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">8 mg</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Median</span></p>
<p><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentiles)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Median</span></p>
<p><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentiles)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Median</span></p>
<p><span class="Bold">(25<span class="Sup">th</span>, 75<span class="Sup">th </span>percentiles)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">26 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">placebo</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">-0.9 (-2.8, 0.9)</p>
<p>NÂ =Â 210</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.0 (-0.9, 3.6)</p>
<p>NÂ =Â 436</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">3.1 (1.1, 5.8)</p>
<p>NÂ =Â 439</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">52 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">sulfonylurea</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">2.0 (0, 4.0)</p>
<p>NÂ =Â 173</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.0 (-0.6, 4.0)</p>
<p>NÂ =Â 150</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.6 (0, 5.3)</p>
<p>NÂ =Â 157</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Combination Therapy</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Sulfonylurea</p></td>
<td class="Botrule Rrule" align="center"><p class="First">24-26 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">sulfonylurea</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0 (-1.0, 1.3)</p>
<p>NÂ =Â 1,155</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.2 (0.5, 4.0)</p>
<p>NÂ =Â 613</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">3.5 (1.4, 5.9)</p>
<p>NÂ =Â 841</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Metformin</p></td>
<td class="Botrule Rrule" align="center"><p class="First">26 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">metformin</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">-1.4 (-3.2, 0.2)</p>
<p>NÂ =Â 175</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.8 (-1.0, 2.6)</p>
<p>NÂ =Â 100</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.1 (0, 4.3)</p>
<p>NÂ =Â 184</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Insulin</p></td>
<td class="Botrule Rrule" align="center"><p class="First">26 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">insulin</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.9 (-0.5, 2.7)</p>
<p>NÂ =Â 162</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">4.1 (1.4, 6.3)</p>
<p>NÂ =Â 164</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">5.4 (3.4, 7.3)</p>
<p>NÂ =Â 150</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Sulfonylurea + metformin</p></td>
<td class="Botrule Rrule" align="center"><p class="First">26 weeks</p></td>
<td class="Botrule Rrule" align="center"><p class="First">sulfonylurea + metformin</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.2 (-1.2, 1.6)</p>
<p>NÂ =Â 272</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.5 (0.8, 4.6)</p>
<p>NÂ =Â 275</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">4.5 (2.4, 7.3)</p>
<p>NÂ =Â 276</p>
</td>
</tr>
</tbody>
</table>
<p>In a 4- to 6-year, monotherapy, comparative trial (ADOPT) in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> not previously treated with antidiabetic medication <span class="Italics">[see Clinical Studies (14.1)]</span>, the median weight change (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentiles) from baseline at 4 years was 3.5 kg (0.0, 8.1) for AVANDIA, 2.0 kg (-1.0, 4.8) for glyburide, and -2.4 kg (-5.4, 0.5) for metformin.</p>
<p>In a 24-week trial in pediatric patients aged 10 to 17Â years treated with AVANDIA 4 to 8Â mg daily, a median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 2.8Â kg (25<span class="Sup">th</span>, 75<span class="Sup">th</span> percentiles: 0.0, 5.8) was reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8c882d3-e208-4e88-956e-3a5e706ecbd3"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatic Effects</h2>
<p class="First">Liver enzymes should be measured prior to the initiation of therapy with AVANDIA in all patients and periodically thereafter per the clinical judgment of the healthcare professional. Therapy with AVANDIA should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt;2.5X upper limit of normal). Patients with mildly elevated liver enzymes (ALT levels â‰¤2.5X upper limit of normal) at baseline or during therapy with AVANDIA should be evaluated to determine the cause of the liver enzyme elevation. Initiation of, or continuation of, therapy with AVANDIA in patients with mild liver enzyme elevations should proceed with caution and include close clinical follow-up, including liver enzyme monitoring, to determine if the liver enzyme elevations resolve or worsen. If at any time ALT levels increase to &gt;3X the upper limit of normal in patients on therapy with AVANDIA, liver enzyme levels should be rechecked as soon as possible. If ALT levels remain &gt;3X the upper limit of normal, therapy with AVANDIA should be discontinued.</p>
<p>If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with AVANDIA should be guided by clinical judgment pending laboratory evaluations. If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is observed, drug therapy should be discontinued. <span class="Italics">[See Adverse Reactions (6.2, 6.3).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_94000f3a-f395-4d73-8e9f-124f76d50461"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported in postmarketing experience in some diabetic patients who were taking AVANDIA or another thiazolidinedione. Some patients presented with <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination. Most patients had <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> at the time <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> was diagnosed. Some patients had improvement in their <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> after discontinuation of their thiazolidinedione. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should have regular eye exams by an ophthalmologist, per the Standards of Care of the American <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Association. Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patientâ€™s underlying medications or other physical findings. <span class="Italics">[See Adverse Reactions (6.1).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4c5cad3-b747-4fd8-95a1-4c14b0e15b21"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></h2>
<p class="First">Long-term trials (ADOPT and RECORD) show an increased incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in patients, particularly female patients, taking AVANDIA <span class="Italics">[see Adverse Reactions (6.1)].</span> This increased incidence was noted after the first year of treatment and persisted during the course of the trial. The majority of the <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in the women who received AVANDIA occurred in the upper arm, hand, and foot. These sites of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> are different from those usually associated with postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (e.g., hip or spine). Other trials suggest that this risk may also apply to men, although the risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> among women appears higher than that among men. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered in the care of patients treated with AVANDIA, and attention given to assessing and maintaining bone health according to current standards of care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f89e10b-90ab-420e-815f-6133e7190498"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Hematologic Effects</h2>
<p class="First">Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with AVANDIA <span class="Italics">[see Adverse Reactions (6.2)]</span>. The observed changes may be related to the increased plasma volume observed with treatment with AVANDIA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_639e548a-a7bd-4ebb-b8ba-1527a630960b"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and Blood Glucose Control</h2>
<p class="First">Patients receiving AVANDIA in combination with other hypoglycemic agents may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and a reduction in the dose of the concomitant agent may be necessary.</p>
<p>Periodic fasting blood glucose and HbA1c measurements should be performed to monitor therapeutic response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_92ec2472-5112-49df-8a98-e0981f9ccec8"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Ovulation</h2>
<p class="First">Therapy with AVANDIA, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking AVANDIA <span class="Italics">[see Use in Specific Populations (8.1)]</span>. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical trials; therefore, the frequency of this occurrence is not known.</p>
<p>Although hormonal imbalance has been seen in preclinical studies <span class="Italics">[see Nonclinical Toxicology (13.1)]</span>, the clinical significance of this finding is not known. If unexpected menstrual dysfunction occurs, the benefits of continued therapy with AVANDIA should be reviewed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_34246020-80bf-4b9e-9330-f4d71b21f713"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail elsewhere in the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>â€¢</dt>
<dd>Major Adverse Cardiovascular Events <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</dd>
<dt>â€¢</dt>
<dd>Hepatic Effects <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span> <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>
</dd>
<dt>â€¢</dt>
<dd>Hematologic Effects <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</dd>
<dt>â€¢</dt>
<dd>Ovulation <span class="Italics">[see Warnings and Precautions (5.10)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5518f874-7f58-454e-a001-e8ab86bc6eeb"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Adult:</span> In clinical trials, approximately 9,900Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with AVANDIA.</p>
<p><span class="Italics">Short-term Trials of AVANDIA as Monotherapy and in Combination With Other Hypoglycemic Agents:</span> The incidence and types of adverse events reported in short-term clinical trials of AVANDIA as monotherapy are shown in Table 3.</p>
<a name="_RefID0E5FAI"></a><table width="100%">
<caption><span>Table 3. Adverse Events (â‰¥5% in any Treatment Group) Reported by Patients in Short-term<span class="Sup">a</span> Double-blind Clinical Trials With AVANDIA as Monotherapy</span></caption>
<col width="32%">
<col width="27%">
<col width="10%">
<col width="13%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">AVANDIA Monotherapy</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Metformin</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Sulfonylureas<span class="Sup">b</span></span></p></td>
</tr>
<tr>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">NÂ =Â 2,526</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">NÂ =Â 601</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">NÂ =Â 225</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">NÂ =Â 626</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">%</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Injury</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.9</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â Short-term trials ranged from 8 weeks to 1 year.</p>
<p><span class="Sup">b</span>Â Â Â Includes patients receiving glyburide (NÂ =Â 514), gliclazide (NÂ =Â 91), or glipizide (NÂ =Â 21).</p>
<p>Overall, the types of adverse reactions without regard to causality reported when AVANDIA was used in combination with a sulfonylurea or metformin were similar to those during monotherapy with AVANDIA.</p>
<p>Events of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> tended to be reported more frequently at higher doses, and were generally mild to moderate in severity and usually did not require discontinuation of treatment with AVANDIA.</p>
<p>In double-blind trials, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was reported in 1.9% of patients receiving AVANDIA as monotherapy compared with 0.7% on placebo, 0.6% on sulfonylureas, and 2.2% on metformin. Reports of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> were greater in patients treated with a combination of AVANDIA and metformin (7.1%) and with a combination of AVANDIA and a sulfonylurea plus metformin (6.7%) compared with monotherapy with AVANDIA or in combination with a sulfonylurea (2.3%). Lower pre-treatment hemoglobin/hematocrit levels in patients enrolled in the metformin combination clinical trials may have contributed to the higher reporting rate of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in these trials <span class="Italics">[see Adverse Reactions (6.2)]</span>.</p>
<p>In clinical trials, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in 4.8% of patients receiving AVANDIA as monotherapy compared with 1.3% on placebo, 1.0% on sulfonylureas, and 2.2% on metformin. The reporting rate of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was higher for AVANDIA 8Â mg in sulfonylurea combinations (12.4%) compared with other combinations, with the exception of insulin. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> was reported in 14.7% of patients receiving AVANDIA in the insulin combination trials compared with 5.4% on insulin alone. Reports of new onset or exacerbation of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> occurred at rates of 1% for insulin alone, and 2% (4Â mg) and 3% (8Â mg) for insulin in combination with AVANDIA <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</p>
<p>In controlled combination therapy trials with sulfonylureas, mild to moderate hypoglycemic symptoms, which appear to be dose related, were reported. Few patients were withdrawn for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (&lt;1%) and few episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were considered to be severe (&lt;1%). <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was the most frequently reported adverse event in the fixed-dose insulin combination trials, although few patients withdrew for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (4 of 408 for AVANDIA plus insulin and 1 of 203 for insulin alone). Rates of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, confirmed by capillary blood glucose concentration â‰¤50Â mg/dL, were 6% for insulin alone and 12% (4Â mg) and 14% (8Â mg) for insulin in combination with AVANDIA. <span class="Italics">[See Warnings and Precautions (5.9).]</span></p>
<p><span class="Italics">Long-term Trial of AVANDIA as Monotherapy:</span> A 4- to 6-year trial (ADOPT) compared the use of AVANDIA (nÂ =Â 1,456), glyburide (nÂ =Â 1,441), and metformin (nÂ =Â 1,454) as monotherapy in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who were not previously treated with antidiabetic medication. Table 4 presents adverse reactions without regard to causality; rates are expressed per 100 patient-years (PY) exposure to account for the differences in exposure to trial medication across the 3 treatment groups.</p>
<p>In ADOPT, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were reported in a greater number of women treated with AVANDIA (9.3%, 2.7/100 patient-years) compared with glyburide (3.5%, 1.3/100 patient-years) or metformin (5.1%, 1.5/100 patient-years). The majority of the <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in the women who received rosiglitazone were reported in the upper arm, hand, and foot. <span class="Italics">[See Warnings and Precautions (5.7).]</span> The observed incidence of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> for male patients was similar among the 3 treatment groups.</p>
<a name="_RefID0ENRAI"></a><table width="100%">
<caption><span>Table 4. On-therapy Adverse Events [â‰¥5 Events/100 Patient-Years (PY)] in any Treatment Group Reported in a 4- to 6-Year Clinical Trial of AVANDIA as Monotherapy (ADOPT)</span></caption>
<col width="45%">
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">AVANDIA</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Glyburide</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 1,456</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 1,441</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 1,454</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">PY = 4,954</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">PY = 4,244</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">PY = 4,906</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.8</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Long-term Trial of AVANDIA as Combination Therapy (RECORD):</span> RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>) was a multicenter, randomized, open-label, non-inferiority trial in subjects with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on maximum doses of metformin or sulfonylurea (glyburide, gliclazide, or glimepiride) to compare the time to reach the combined cardiovascular endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or cardiovascular hospitalization between patients randomized to the addition of AVANDIA versus metformin or sulfonylurea. The trial included patients who have failed metformin or sulfonylurea monotherapy; those who failed metformin (nÂ =Â 2,222) were randomized to receive either AVANDIA as add-on therapy (nÂ =Â 1,117) or add-on sulfonylurea (nÂ =Â 1,105), and those who failed sulfonylurea (nÂ =Â 2,225) were randomized to receive either AVANDIA as add-on therapy (nÂ =Â 1,103) or add-on metformin (nÂ =Â 1,122). Patients were treated to target HbA1c â‰¤7% throughout the trial.</p>
<p>The mean age of patients in this trial was 58 years, 52% were male, and the mean duration of follow-up was 5.5Â years. AVANDIA demonstrated non-inferiority to active control for the primary endpoint of cardiovascular hospitalization or cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (HR 0.99, 95% CI: 0.85-1.16). There were no significant differences between groups for secondary endpoints with the exception of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see Table 5). The incidence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> was significantly greater among patients randomized to AVANDIA.</p>
<a name="_RefID0EGJAI"></a><table width="100%">
<caption><span>Table 5. Cardiovascular (CV) Outcomes for the RECORD Trial</span></caption>
<col width="42%">
<col width="13%">
<col width="17%">
<col width="16%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Primary Endpoint</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">NÂ =Â 2,220</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Active Control</span></p>
<p><span class="Bold">N = 2,227</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Hazard Ratio</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">95% CI</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or CV hospitalization</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">321</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">323</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.99</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.85-1.16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Secondary Endpoint</span></p></td>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
<td class="Botrule Lrule Rrule" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">136</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">157</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.86</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.68-1.08</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.84</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.59-1.18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.14</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.80-1.63</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">63</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.72</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.49-1.06</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">154</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">165</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.93</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.74-1.15</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">61</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.35-3.27</p></td>
</tr>
</tbody>
</table>
<p>There was an increased incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> for subjects randomized to AVANDIA in addition to metformin or sulfonylurea compared with those randomized to metformin plus sulfonylurea (8.3% versus 5.3%) <span class="Italics">[see Warnings and Precautions (5.7)]</span>. The majority of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were reported in the upper limbs and distal lower limbs. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> appeared to be higher in females relative to control (11.5% versus 6.3%), than in males relative to control (5.3% versus 4.3%). Additional data are necessary to determine whether there is an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in males after a longer period of follow-up.</p>
<p><span class="Underline">Pediatric:</span> AVANDIA has been evaluated for safety in a single, active-controlled trial of pediatric patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in which 99 were treated with AVANDIA and 101 were treated with metformin. The most common adverse reactions (&gt;10%) without regard to causality for either AVANDIA or metformin were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17% versus 14%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4% versus 11%), <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (3% versus 12%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1% versus 13%). In this trial, one case of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> was reported in the metformin group. In addition, there were 3 patients in the rosiglitazone group who had FPG of approximately 300 mg/dL, 2+ <span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span>, and an elevated <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_896cc05d-05a7-4f7f-83d9-7288fc17e6bf"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Laboratory Abnormalities</h2>
<p class="First"><span class="Underline">Hematologic:</span> Decreases in mean hemoglobin and hematocrit occurred in a dose-related fashion in adult patients treated with AVANDIA (mean decreases in individual trials as much as 1.0Â g/dL hemoglobin and as much as 3.3% hematocrit). The changes occurred primarily during the first 3Â months following initiation of therapy with AVANDIA or following a dose increase in AVANDIA. The time course and magnitude of decreases were similar in patients treated with a combination of AVANDIA and other hypoglycemic agents or monotherapy with AVANDIA. Pre-treatment levels of hemoglobin and hematocrit were lower in patients in metformin combination trials and may have contributed to the higher reporting rate of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. In a single trial in pediatric patients, decreases in hemoglobin and hematocrit (mean decreases of 0.29Â g/dL and 0.95%, respectively) were reported. Small decreases in hemoglobin and hematocrit have also been reported in pediatric patients treated with AVANDIA. White blood cell counts also decreased slightly in adult patients treated with AVANDIA. Decreases in hematologic parameters may be related to increased plasma volume observed with treatment with AVANDIA.</p>
<p><span class="Underline">Lipids:</span> Changes in serum lipids have been observed following treatment with AVANDIA in adults <span class="Italics">[see Clinical Pharmacology (12.2)]</span>. Small changes in serum lipid parameters were reported in children treated with AVANDIA for 24Â weeks.</p>
<p><span class="Underline">Serum Transaminase Levels:</span> In pre-approval clinical trials in 4,598Â patients treated with AVANDIA (3,600Â patient-years of exposure) and in a long-term 4- to 6-year trial in 1,456 patients treated with AVANDIA (4,954 patient-years exposure), there was no evidence of drug-induced hepatotoxicity.</p>
<p>In pre-approval controlled trials, 0.2% of patients treated with AVANDIA had elevations in ALT &gt;3X the upper limit of normal compared with 0.2% on placebo and 0.5% on active comparators. The ALT elevations in patients treated with AVANDIA were reversible. <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> was found in 0.3% of patients treated with AVANDIA compared with 0.9% treated with placebo and 1% in patients treated with active comparators. In pre-approval clinical trials, there were no cases of idiosyncratic drug reactions leading to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. <span class="Italics">[See Warnings and Precautions (5.5).]</span></p>
<p>In the 4- to 6-year ADOPT trial, patients treated with AVANDIA (4,954 patient-years exposure), glyburide (4,244 patient-years exposure), or metformin (4,906 patient-years exposure), as monotherapy, had the same rate of ALT increase to &gt;3X upper limit of normal (0.3Â per 100 patient-years exposure). </p>
<p>In the RECORD trial, patients randomized to AVANDIA in addition to metformin or sulfonylurea (10,849 patient-years exposure) and to metformin plus sulfonylurea (10,209 patient-years exposure) had a rate of ALT increase to â‰¥3X upper limit of normal of approximately 0.2 and 0.3 per 100 patient-years exposure, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3a3feb87-51ac-4a14-90c3-5e655bacb4eb"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of AVANDIA. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.</p>
<p>In patients receiving thiazolidinedione therapy, serious adverse events with or without a fatal outcome, potentially related to volume expansion (e.g., <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>) have been reported <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</p>
<p>There are postmarketing reports with AVANDIA of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic enzyme elevations to 3 or more times the upper limit of normal, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> with and without fatal outcome, although causality has not been established.</p>
<p>There are postmarketing reports with AVANDIA of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> <span class="Italics">[see Contraindications (4)]</span>, and new onset or worsening <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> with decreased visual acuity <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_90f2a00f-e144-47c1-9acc-dd76e80e44b4"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1ccab237-cb94-4563-9c0d-4c45e9576e66"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP2C8 Inhibitors and Inducers</h2>
<p class="First">An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatment may be needed based upon clinical response. <span class="Italics">[See Clinical Pharmacology (12.4).]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_60e13821-fd03-4145-956a-b08eb9c45067"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_db48ce6c-2643-4208-baa6-eaf72a476077"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may be decreased with good metabolic control. It is essential for patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or history of <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> to maintain good metabolic control before conception and throughout pregnancy. Careful monitoring of glucose control is essential in such patients. Most experts recommend that insulin monotherapy be used during pregnancy to maintain blood glucose levels as close to normal as possible.</p>
<p><span class="Underline">Human Data:</span> Rosiglitazone has been reported to cross the human placenta and be detectable in fetal tissue. The clinical significance of these findings is unknown. There are no adequate and well-controlled trials in pregnant women. AVANDIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Underline">Animal Studies:</span> There was no effect on implantation or the embryo with rosiglitazone treatment during early pregnancy in rats, but treatment during mid-late gestation was associated with <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> in both rats and rabbits. <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> was not observed at doses up to 3Â mg/kg in rats and 100Â mg/kg in rabbits (approximately 20 and 75Â times human AUC at the maximum recommended human daily dose, respectively). Rosiglitazone caused placental pathology in rats (3Â mg/kg/day). Treatment of rats during gestation through lactation reduced litter size, neonatal viability, and postnatal growth, with <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> reversible after puberty. For effects on the placenta, embryo/fetus, and offspring, the no-effect dose was 0.2Â mg/kg/day in rats and 15 mg/kg/day in rabbits. These no-effect levels are approximately 4Â times human AUC at the maximum recommended human daily dose. Rosiglitazone reduced the number of uterine implantations and live offspring when juvenile female rats were treated at 40Â mg/kg/day from 27Â days of age through to sexual maturity (approximately 68Â times human AUC at the maximum recommended daily dose). The no-effect level was 2Â mg/kg/day (approximately 4Â times human AUC at the maximum recommended daily dose). There was no effect on pre- or post-natal survival or growth.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_04d118a0-a731-47df-a2c5-a6752d082fdb"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of rosiglitazone on labor and delivery in humans is not known.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_68254538-5fe5-44f7-9bf0-72658c57fb6b"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Drug-related material was detected in milk from lactating rats. It is not known whether AVANDIA is excreted in human milk. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue AVANDIA, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_7c24928b-262f-4fca-af12-5230016441ab"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">After placebo run-in including diet counseling, children with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, aged 10 to 17Â years and with a baseline mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) of 33Â kg/m<span class="Sup">2</span>, were randomized to treatment with 2Â mg twice daily of AVANDIA (nÂ =Â 99) or 500Â mg twice daily of metformin (nÂ =Â 101) in a 24-week, double-blind clinical trial. As expected, FPG decreased in patients naÃ¯ve to <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication (nÂ =Â 104) and increased in patients withdrawn from prior medication (usually metformin) (nÂ =Â 90) during the run-in period. After at least 8Â weeks of treatment, 49% of patients treated with AVANDIA and 55% of metformin-treated patients had their dose doubled if FPG &gt;126Â mg/dL. For the overall intent-to-treat population, at WeekÂ 24, the mean change from baseline in HbA1c was -0.14% with AVANDIA and -0.49% with metformin. There was an insufficient number of patients in this trial to establish statistically whether these observed mean treatment effects were similar or different. Treatment effects differed for patients naÃ¯ve to therapy with antidiabetic drugs and for patients previously treated with antidiabetic therapy (Table 6).</p>
<a name="_RefID0EW4AI"></a><table width="100%">
<caption><span>Table 6. Week 24 FPG and HbA1c Change From Baseline Last-observationâ€”carried Forward in Children With Baseline HbA1c &gt;6.5%</span></caption>
<col width="50%">
<col width="11%">
<col width="13%">
<col width="11%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">NaÃ¯ve Patients</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Previously-treated Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Metformin</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Rosiglitazone</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Metformin</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Rosiglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N = 40</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N = 45</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N = 43</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N = 32</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">170</p></td>
<td class="Rrule" align="center"><p class="First">165</p></td>
<td class="Rrule" align="center"><p class="First">221</p></td>
<td class="Rrule" align="center"><p class="First">205</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">-21</p></td>
<td class="Rrule" align="center"><p class="First">-11</p></td>
<td class="Rrule" align="center"><p class="First">-33</p></td>
<td class="Rrule" align="center"><p class="First">-5</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Adjusted treatment difference<span class="Sup">	a</span>
</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Â Â Â Â Â (rosiglitazoneâ€“metformin)<span class="Sup">	b</span>
</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">8</p></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">21</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Â Â Â Â Â (95% CI)</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">(-15, 30)</p></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">(-9, 51)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30 mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">43%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">44%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8.3</p></td>
<td class="Rrule" align="center"><p class="First">8.2</p></td>
<td class="Rrule" align="center"><p class="First">8.8</p></td>
<td class="Rrule" align="center"><p class="First">8.5</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">-0.7</p></td>
<td class="Rrule" align="center"><p class="First">-0.5</p></td>
<td class="Rrule" align="center"><p class="First">-0.4</p></td>
<td class="Rrule" align="center"><p class="First">0.1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Adjusted treatment difference<span class="Sup">	a</span>
</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Â Â Â Â Â (rosiglitazoneâ€“metformin)<span class="Sup">	b</span>
</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">0.2</p></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Â Â Â Â Â (95% CI)</dd>
</dl></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">(-0.6, 0.9)</p></td>
<td class="Rrule"></td>
<td class="Rrule" align="center"><p class="First">(-0.2, 1.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">63%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">52%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">54%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">31%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â Change from baseline means are least squares means adjusting for baseline HbA1c, gender, and region.</p>
<p><span class="Sup">b</span>Â Â Â Positive values for the difference favor metformin.</p>
<p>Treatment differences depended on baseline BMI or weight such that the effects of AVANDIA and metformin appeared more closely comparable among heavier patients. The median <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 2.8Â kg with rosiglitazone and 0.2Â kg with metformin <span class="Italics">[see Warnings and Precautions (5.4)]</span>. Fifty-four percent of patients treated with rosiglitazone and 32% of patients treated with metformin gained â‰¥2Â kg, and 33% of patients treated with rosiglitazone and 7% of patients treated with metformin gained â‰¥5Â kg on trial.</p>
<p>Adverse events observed in this trial are described in <span class="Italics">Adverse Reactions (6.1)</span>.</p>
<p><span class="Bold">Figure 2. Mean HbA1c Over Time in a 24-Week Trial of AVANDIA and Metformin in Pediatric Patients â€” Drug-naÃ¯ve Subgroup</span></p>
<div class="Figure">
<a name="id21608968"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_2ca742dd-1975-4d3e-a2aa-96b35394b5cf"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Results of the population pharmacokinetic analysis showed that age does not significantly affect the pharmacokinetics of rosiglitazone <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Therefore, no dosage adjustments are required for the elderly. In controlled clinical trials, no overall differences in safety and effectiveness between older (â‰¥65 years) and younger (&lt;65 years) patients were observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_6ee2c012-9620-4bc6-9eaa-f401d879a50b"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Limited data are available with regard to overdosage in humans. In clinical trials in volunteers, AVANDIA has been administered at single oral doses of up to 20Â mg and was well tolerated. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive treatment should be initiated as dictated by the patientâ€™s clinical status.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_34175dab-6759-4159-82c6-9224b7eeb2e7"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing circulating insulin levels.</p>
<p>Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.</p>
<p>Chemically, rosiglitazone maleate is (Â±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, (<span class="Italics">Z</span>)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base). The molecule has a single chiral center and is present as a racemate. Due to rapid interconversion, the enantiomers are functionally indistinguishable. The structural formula of rosiglitazone maleate is:</p>
<div class="Figure">
<a name="id13683070"></a><img alt="rosiglitazone maleate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-03.jpg">
</div>
<p>The molecular formula is C<span class="Sub">18</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">3</span>Sâ€¢C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>. Rosiglitazone maleate is a white to off-white solid with a melting point range of 122Â° to 123Â°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1. It is readily soluble in ethanol and a buffered aqueous solution with pH of 2.3; solubility decreases with increasing pH in the physiological range.</p>
<p>Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent to rosiglitazone, 2Â mg, 4Â mg, or 8Â mg, for oral administration. Inactive ingredients are: hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide, triacetin, and 1 or more of the following: synthetic red and yellow iron oxides and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f0cd30e8-1c7c-4bdc-858b-bdf07205ce86"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_82ec0da8-c635-4d69-b5c1-80c1755fa1df"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Rosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARÎ³). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARÎ³ nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPARÎ³-responsive genes also participate in the regulation of fatty acid metabolism.</p>
<p><span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">Insulin resistance</span> is a common feature characterizing the pathogenesis of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The antidiabetic activity of rosiglitazone has been demonstrated in animal models of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> in which <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and/or impaired glucose tolerance is a consequence of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span> in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.</p>
<p>In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulinâ€™s action in the liver, muscle, and adipose tissues. Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in animal models of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and/or impaired glucose tolerance.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_d9077ce5-1130-4645-8023-730f54a998dd"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Patients with lipid abnormalities were not excluded from clinical trials of AVANDIA. In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL, and HDL and decreases in free fatty acids. These changes were statistically significantly different from placebo or glyburide controls (Table 7).</p>
<p>Increases in LDL occurred primarily during the first 1 to 2Â months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2Â months of therapy and then appeared to decrease over time. Because of the temporal nature of lipid changes, the 52-week, glyburide-controlled trial is most pertinent to assess long-term effects on lipids. At baseline, WeekÂ 26, and WeekÂ 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4Â mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9. The differences in change from baseline between AVANDIA and glyburide at WeekÂ 52 were statistically significant.</p>
<p>The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.</p>
<p>The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls.</p>
<a name="_RefID0E5MBI"></a><table width="100%">
<caption><span>Table 7. Summary of Mean Lipid Changes in 26-Week, Placebo-controlled and 52-Week, Glyburide-controlled Monotherapy Trials</span></caption>
<col width="35%">
<col width="9%">
<col width="11%">
<col width="11%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First"><span class="Bold">Placebo-controlled Trials</span></p>
<p><span class="Bold">Week 26</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="bottom">
<p class="First"><span class="Bold">Glyburide-controlled Trial</span></p>
<p><span class="Bold">Week 26 and Week 52</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">AVANDIA</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Glyburide Titration</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">AVANDIA 8 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">4 mg Daily<span class="Sup">a</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">8 mg Daily<span class="Sup">a</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Week 26</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Week 52</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Week 26</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Week 52</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Free fatty acids</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	N</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">207</p></td>
<td class="Rrule" align="center"><p class="First">428</p></td>
<td class="Rrule" align="center"><p class="First">436</p></td>
<td class="Rrule" align="center"><p class="First">181</p></td>
<td class="Rrule" align="center"><p class="First">168</p></td>
<td class="Rrule" align="center"><p class="First">166</p></td>
<td class="Rrule" align="center"><p class="First">145</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">18.1</p></td>
<td class="Rrule" align="center"><p class="First">17.5</p></td>
<td class="Rrule" align="center"><p class="First">17.9</p></td>
<td class="Rrule" align="center"><p class="First">26.4</p></td>
<td class="Rrule" align="center"><p class="First">26.4</p></td>
<td class="Rrule" align="center"><p class="First">26.9</p></td>
<td class="Rrule" align="center"><p class="First">26.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% Change from baseline (mean)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">+0.2%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-7.8%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-14.7%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-2.4%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-4.7%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-20.8%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-21.5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">LDL</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	N</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">190</p></td>
<td class="Rrule" align="center"><p class="First">400</p></td>
<td class="Rrule" align="center"><p class="First">374</p></td>
<td class="Rrule" align="center"><p class="First">175</p></td>
<td class="Rrule" align="center"><p class="First">160</p></td>
<td class="Rrule" align="center"><p class="First">161</p></td>
<td class="Rrule" align="center"><p class="First">133</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">123.7</p></td>
<td class="Rrule" align="center"><p class="First">126.8</p></td>
<td class="Rrule" align="center"><p class="First">125.3</p></td>
<td class="Rrule" align="center"><p class="First">142.7</p></td>
<td class="Rrule" align="center"><p class="First">141.9</p></td>
<td class="Rrule" align="center"><p class="First">142.1</p></td>
<td class="Rrule" align="center"><p class="First">142.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% Change from baseline (mean)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">+4.8%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+14.1%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+18.6%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.9%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.5%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+11.9%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+12.1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HDL</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	N</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">208</p></td>
<td class="Rrule" align="center"><p class="First">429</p></td>
<td class="Rrule" align="center"><p class="First">436</p></td>
<td class="Rrule" align="center"><p class="First">184</p></td>
<td class="Rrule" align="center"><p class="First">170</p></td>
<td class="Rrule" align="center"><p class="First">170</p></td>
<td class="Rrule" align="center"><p class="First">145</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">44.1</p></td>
<td class="Rrule" align="center"><p class="First">44.4</p></td>
<td class="Rrule" align="center"><p class="First">43.0</p></td>
<td class="Rrule" align="center"><p class="First">47.2</p></td>
<td class="Rrule" align="center"><p class="First">47.7</p></td>
<td class="Rrule" align="center"><p class="First">48.4</p></td>
<td class="Rrule" align="center"><p class="First">48.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% Change from baseline (mean)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">+8.0%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+11.4%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+14.2%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+4.3%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+8.7%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+14.0%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">+18.5%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â Once-daily and twice-daily dosing groups were combined.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_5fdbbd2e-3d59-4af3-8d48-e73981ebc597"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Maximum plasma concentration (C<span class="Sub">max</span>) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (TableÂ 8). The elimination half-life is 3 to 4Â hours and is independent of dose.</p>
<a name="_RefID0EH6BI"></a><table width="100%">
<caption><span>Table 8. Mean (SD) Pharmacokinetic Parameters for Rosiglitazone Following Single Oral Doses (NÂ =Â 32)</span></caption>
<col width="42%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">1 mg</span></p>
<p><span class="Bold">Fasting</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">2 mg</span></p>
<p><span class="Bold">Fasting</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">8 mg</span></p>
<p><span class="Bold">Fasting</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">8 mg</span></p>
<p><span class="Bold">Fed</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">AUC<span class="Sub">0-inf</span></p></td>
<td class="Rrule" align="center"><p class="First">358</p></td>
<td class="Rrule" align="center"><p class="First">733</p></td>
<td class="Rrule" align="center"><p class="First">2,971</p></td>
<td class="Rrule" align="center"><p class="First">2,890</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	(ng.h/mL)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">(112)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(184)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(730)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(795)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">C<span class="Sub">max</span></p></td>
<td class="Rrule" align="center"><p class="First">76</p></td>
<td class="Rrule" align="center"><p class="First">156</p></td>
<td class="Rrule" align="center"><p class="First">598</p></td>
<td class="Rrule" align="center"><p class="First">432</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	(ng/mL)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">(13)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(42)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(117)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(92)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">TÂ½</p></td>
<td class="Rrule" align="center"><p class="First">3.16</p></td>
<td class="Rrule" align="center"><p class="First">3.15</p></td>
<td class="Rrule" align="center"><p class="First">3.37</p></td>
<td class="Rrule" align="center"><p class="First">3.59</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	(h)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.72)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.39)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.63)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.70)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">CL/F</p></td>
<td class="Rrule" align="center"><p class="First">3.03</p></td>
<td class="Rrule" align="center"><p class="First">2.89</p></td>
<td class="Rrule" align="center"><p class="First">2.85</p></td>
<td class="Rrule" align="center"><p class="First">2.97</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	(L/h)</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.87)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.71)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.69)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(0.81)</p></td>
</tr>
</tbody>
</table>
<p>AUCÂ =Â area under the curve; C<span class="Sub">max</span>Â =Â maximum concentration; T<span class="Sub">Â½</span>Â =Â terminal half-life; CL/FÂ =Â Oral clearance.</p>
<p><span class="Underline">Absorption:</span> The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1Â hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in C<span class="Sub">max</span> and a delay in T<span class="Sub">max</span> (1.75Â hours). These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food.</p>
<p><span class="Underline">Distribution:</span> The mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.</p>
<p><span class="Underline">Metabolism:</span> Rosiglitazone is extensively metabolized with no unchanged drug excreted in the urine. The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone.</p>
<p>In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.</p>
<p><span class="Underline">Excretion:</span> Following oral or intravenous administration of [<span class="Sup">14</span>C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [<span class="Sup">14</span>C]related material ranged from 103 to 158Â hours.</p>
<p><span class="Underline">Population Pharmacokinetics in Patients With TypeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>:</span> Population pharmacokinetic analyses from 3 large clinical trials including 642Â men and 405Â women with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (aged 35 to 80Â years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption. Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 to 150Â kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively. Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics">Geriatric:</span> Results of the population pharmacokinetic analysis (nÂ =Â 716 &lt;65Â years; nÂ =Â 331 â‰¥65Â years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone.</p>
<p><span class="Italics">Gender:</span> Results of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (nÂ =Â 405) was approximately 6% lower compared with male patients of the same body weight (nÂ =Â 642).</p>
<p>As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females. In metformin combination trials, efficacy was demonstrated with no gender differences in glycemic response.</p>
<p>In monotherapy trials, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident. For a given body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI), females tend to have a greater fat <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> than males. Since the molecular target PPARÎ³ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females. Since therapy should be individualized, no dose adjustments are necessary based on gender alone.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Unbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared with healthy subjects. As a result, unbound C<span class="Sub">max</span> and AUC<span class="Sub">0-inf</span> were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared with healthy subjects.</p>
<p>Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
<p><span class="Italics">Pediatric:</span> Pharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17Â years (weights ranging from 35 to 178.3Â kg). Population mean CL/F and V/F of rosiglitazone were 3.15 L/h and 13.5 L, respectively. These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> There are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in hemodialysis-dependent patients compared with subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving AVANDIA. Since metformin is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, coadministration of metformin with AVANDIA is contraindicated in these patients.</p>
<p><span class="Italics">Race:</span> Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61c7478b-5c3e-4575-817d-455b999dd608"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Drug-drug Interactions</h2>
<p class="First"><span class="Underline">Drugs That Inhibit, Induce, or are Metabolized by Cytochrome P450:</span> In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9. AVANDIA (4Â mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.</p>
<p><span class="Italics">Gemfibrozil:</span> Concomitant administration of gemfibrozil (600Â mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4Â mg once daily) for 7Â days increased rosiglitazone AUC by 127%, compared with the administration of rosiglitazone (4Â mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced <span class="Italics">[see Drug Interactions (7.1)]</span>.</p>
<p><span class="Italics">Rifampin:</span> Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared with the administration of rosiglitazone (8 mg) alone <span class="Italics">[see Drug Interactions (7.1)]</span>.<span class="Sup">1</span></p>
<p><span class="Underline">Glyburide:</span> AVANDIA (2Â mg twice daily) taken concomitantly with glyburide (3.75 to 10Â mg/day) for 7Â days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and C<span class="Sub">max</span> of approximately 30%. In Japanese subjects, glyburide AUC and C<span class="Sub">max</span> slightly increased following coadministration of AVANDIA.</p>
<p><span class="Underline">Glimepiride:</span> Single oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and C<span class="Sub">max</span> were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.</p>
<p><span class="Underline">Metformin:</span> Concurrent administration of AVANDIA (2Â mg twice daily) and metformin (500Â mg twice daily) in healthy volunteers for 4Â days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.</p>
<p><span class="Underline">Acarbose:</span> Coadministration of acarbose (100Â mg three times daily) for 7Â days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.</p>
<p><span class="Underline">Digoxin:</span> Repeat oral dosing of AVANDIA (8Â mg once daily) for 14Â days did not alter the steady-state pharmacokinetics of digoxin (0.375Â mg once daily) in healthy volunteers.</p>
<p><span class="Underline">Warfarin:</span> Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.</p>
<p><span class="Underline">Ethanol:</span> A single administration of a moderate amount of alcohol did not increase the risk of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus patients treated with AVANDIA.</p>
<p><span class="Underline">Ranitidine:</span> Pre-treatment with ranitidine (150Â mg twice daily for 4Â days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_8003df7b-eb7a-4535-b39c-635f092ecd35"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_2f5baf5f-ee93-4f3f-b257-4f1484d69066"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis:</span> A 2-year carcinogenicity study was conducted in Charles River CD-1 mice at doses of 0.4, 1.5, and 6Â mg/kg/day in the diet (highest dose equivalent to approximately 12Â times human AUC at the maximum recommended human daily dose). Sprague-Dawley rats were dosed for 2Â years by oral gavage at doses of 0.05, 0.3, and 2Â mg/kg/day (highest dose equivalent to approximately 10 and 20Â times human AUC at the maximum recommended human daily dose for male and female rats, respectively).</p>
<p>Rosiglitazone was not carcinogenic in the mouse. There was an increase in incidence of adipose <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the mouse at doses â‰¥1.5Â mg/kg/day (approximately 2Â times human AUC at the maximum recommended human daily dose). In rats, there was a significant increase in the incidence of benign adipose tissue tumors (<span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipomas</span>) at doses â‰¥0.3Â mg/kg/day (approximately 2Â times human AUC at the maximum recommended human daily dose). These proliferative changes in both species are considered due to the persistent pharmacological overstimulation of adipose tissue.</p>
<p><span class="Underline">Mutagenesis:</span> Rosiglitazone was not mutagenic or clastogenic in the in vitro bacterial assays for gene mutation, the in vitro chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, the in vivo mouse micronucleus test, and the in vivo<span class="Italics">/</span>in vitro rat UDS assay. There was a small (about 2-fold) increase in mutation in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay in the presence of metabolic activation.</p>
<p><span class="Underline">Impairment of Fertility:</span> Rosiglitazone had no effects on mating or fertility of male rats given up to 40Â mg/kg/day (approximately 116Â times human AUC at the maximum recommended human daily dose). Rosiglitazone altered estrous cyclicity (2Â mg/kg/day) and reduced fertility (40Â mg/kg/day) of female rats in association with lower plasma levels of progesterone and estradiol (approximately 20 and 200Â times human AUC at the maximum recommended human daily dose, respectively). No such effects were noted at 0.2Â mg/kg/day (approximately 3Â times human AUC at the maximum recommended human daily dose). In juvenile rats dosed from 27Â days of age through to sexual maturity (at up to 40Â mg/kg/day), there was no effect on male reproductive performance, or on estrous cyclicity, mating performance or pregnancy incidence in females (approximately 68Â times human AUC at the maximum recommended human daily dose). In monkeys, rosiglitazone (0.6Â and 4.6Â mg/kg/day; approximately 3 and 15Â times human AUC at the maximum recommended human daily dose, respectively) diminished the follicular phase rise in serum estradiol with consequential reduction in the luteinizing hormone surge, lower luteal phase progesterone levels, and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. The mechanism for these effects appears to be direct inhibition of ovarian steroidogenesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6acf3b5b-4fd8-4268-819e-18bb223678a0"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">Heart weights were increased in mice (3Â mg/kg/day), rats (5Â mg/kg/day), and dogs (2Â mg/kg/day) with rosiglitazone treatments (approximately 5, 22, and 2Â times human AUC at the maximum recommended human daily dose, respectively). Effects in juvenile rats were consistent with those seen in adults. Morphometric measurement indicated that there was <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> in cardiac ventricular tissues, which may be due to increased heart work as a result of plasma volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_2c7614ea-ca2a-4e0b-a1b9-872521a1f327"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6416bc29-e1f9-4a69-84d7-3374c6cb1013"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Monotherapy</h2>
<p class="First">In clinical trials, treatment with AVANDIA resulted in an improvement in glycemic control, as measured by FPG and HbA1c, with a concurrent reduction in insulin and C-peptide. Postprandial glucose and insulin were also reduced. This is consistent with the mechanism of action of AVANDIA as an insulin sensitizer. </p>
<p>The maximum recommended daily dose is 8Â mg. Dose-ranging trials suggested that no additional benefit was obtained with a total daily dose of 12Â mg.</p>
<p><span class="Underline">Short-term Clinical Trials:</span> A total of 2,315Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, previously treated with diet alone or antidiabetic medication(s), were treated with AVANDIA as monotherapy in 6 double-blind trials, which included two 26-week, placebo-controlled trials; one 52-week, glyburide-controlled trial; and 3 placebo-controlled, dose-ranging trials of 8 to 12Â weeksâ€™ duration. Previous antidiabetic medication(s) were withdrawn and patients entered a 2- to 4-week placebo run-in period prior to randomization.</p>
<p>Two 26-week, double-blind, placebo-controlled trials, in patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (nÂ =Â 1,401) with inadequate glycemic control [mean baseline FPG approximately 228Â mg/dL (101 to 425Â mg/dL) and mean baseline HbA1c 8.9% (5.2% to 16.2%)], were conducted. Treatment with AVANDIA produced statistically significant improvements in FPG and HbA1c compared with baseline and relative to placebo. Data from one of these trials are summarized in Table 9.</p>
<a name="_RefID0EDMCI"></a><table width="100%">
<caption><span>Table 9. Glycemic Parameters in a 26-Week, Placebo-controlled Trial</span></caption>
<col width="43%">
<col width="9%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">AVANDIA</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">AVANDIA</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">4 mg Once Daily</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">2 mg Twice Daily</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">8 mg Once Daily</span></p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">4 mg Twice Daily</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 173</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 180</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 186</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 181</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 187</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">225</p></td>
<td class="Rrule" align="center"><p class="First">229</p></td>
<td class="Rrule" align="center"><p class="First">225</p></td>
<td class="Rrule" align="center"><p class="First">228</p></td>
<td class="Rrule" align="center"><p class="First">228</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8</p></td>
<td class="Rrule" align="center"><p class="First">-25</p></td>
<td class="Rrule" align="center"><p class="First">-35</p></td>
<td class="Rrule" align="center"><p class="First">-42</p></td>
<td class="Rrule" align="center"><p class="First">-55</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from placebo (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-31<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-43<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-49<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-62<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30 mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">19%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">45%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">54%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">58%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">70%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">9.0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">0.8</p></td>
<td class="Rrule" align="center"><p class="First">0.0</p></td>
<td class="Rrule" align="center"><p class="First">-0.1</p></td>
<td class="Rrule" align="center"><p class="First">-0.3</p></td>
<td class="Rrule" align="center"><p class="First">-0.7</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from placebo (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-0.8<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-0.9<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-1.1<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-1.5<span class="Sup">a</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">29%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">39%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">54%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â <span class="Italics">P</span> &lt;0.0001 compared with placebo. </p>
<p>When administered at the same total daily dose, AVANDIA was generally more effective in reducing FPG and HbA1c when administered in divided doses twice daily compared with once-daily doses. However, for HbA1c, the difference between the 4Â mg once-daily and 2Â mg twice-daily doses was not statistically significant.</p>
<p><span class="Underline">Long-term Clinical Trials:</span> Long-term maintenance of effect was evaluated in a 52-week, double-blind, glyburide-controlled trial in patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Patients were randomized to treatment with AVANDIA 2Â mg twice daily (NÂ =Â 195) or AVANDIA 4Â mg twice daily (NÂ =Â 189) or glyburide (NÂ =Â 202) for 52Â weeks. Patients receiving glyburide were given an initial dosage of either 2.5Â mg/day or 5.0Â mg/day. The dosage was then titrated in 2.5-mg/day increments over the next 12Â weeks, to a maximum dosage of 15.0Â mg/day in order to optimize glycemic control. Thereafter, the glyburide dose was kept constant.</p>
<p>The median titrated dose of glyburide was 7.5Â mg. All treatments resulted in a statistically significant improvement in glycemic control from baseline (Figure 3 and Figure 4). At the end of Week 52, the reduction from baseline in FPG and HbA1c was -40.8 mg/dL and -0.53% with AVANDIA 4Â mg twice daily; -25.4Â mg/dL and -0.27% with AVANDIA 2Â mg twice daily; and -30.0Â mg/dL and -0.72% with glyburide. For HbA1c, the difference between AVANDIA 4Â mg twice daily and glyburide was not statistically significant at WeekÂ 52. The initial <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FPG with glyburide was greater than with AVANDIA; however, this effect was less durable over time. The improvement in glycemic control seen with AVANDIA 4 mg twice daily at WeekÂ 26 was maintained through WeekÂ 52 of the trial.</p>
<p><span class="Bold">Figure 3. Mean FPG Over Time in a 52</span>â€‘<span class="Bold">Week, Glyburide</span>â€‘<span class="Bold">controlled Trial</span></p>
<div class="Figure">
<a name="id13679152"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-04.jpg">
</div>
<p><span class="Bold">Figure 4. Mean HbA1c Over Time in a 52</span>â€‘<span class="Bold">Week, Glyburide</span>â€‘<span class="Bold">controlled Trial</span></p>
<div class="Figure">
<a name="id13679153"></a><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-05.jpg">
</div>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in 12.1% of glyburide-treated patients versus 0.5% (2Â mg twice daily) and 1.6% (4Â mg twice daily) of patients treated with AVANDIA. The improvements in glycemic control were associated with a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 1.75Â kg and 2.95Â kg for patients treated with 2Â mg and 4Â mg twice daily of AVANDIA, respectively, versus 1.9Â kg in glyburide-treated patients. In patients treated with AVANDIA, C-peptide, insulin, pro-insulin, and pro-insulin split products were significantly reduced in a dose-ordered fashion, compared with an increase in the glyburide-treated patients.</p>
<p>A <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Outcome Progression Trial (ADOPT) was a multicenter, double-blind, controlled trial (NÂ =Â 4,351) conducted over 4 to 6 years to compare the safety and efficacy of AVANDIA, metformin, and glyburide monotherapy in patients recently diagnosed with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (â‰¤3 years) inadequately controlled with diet and exercise. The mean age of patients in this trial was 57Â years and the majority of patients (83%) had no known history of cardiovascular disease. The mean baseline FPG and HbA1c were 152Â mg/dL and 7.4%, respectively. Patients were randomized to receive either AVANDIA 4Â mg once daily, glyburide 2.5Â mg once daily, or metformin 500Â mg once daily, and doses were titrated to optimal glycemic control up to a maximum of 4Â mg twice daily for AVANDIA, 7.5Â mg twice daily for glyburide, and 1,000Â mg twice daily for metformin. The primary efficacy outcome was time to consecutive FPG &gt;180Â mg/dL after at least 6Â weeks of treatment at the maximum tolerated dose of study medication or time to inadequate glycemic control, as determined by an independent adjudication committee.</p>
<p>The cumulative incidence of the primary efficacy outcome at 5Â years was 15% with AVANDIA, 21% with metformin, and 34% with glyburide (HR 0.68 [95% CI: 0.55, 0.85] versus metformin, HR 0.37 [95% CI: 0.30, 0.45] versus glyburide).</p>
<p>Cardiovascular and adverse event data (including effects on body weight and bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>) from ADOPT for AVANDIA, metformin, and glyburide are described in <span class="Italics">Warnings and Precautions (5.2, 5.4, and 5.7)</span> and <span class="Italics">Adverse Reactions (6.1)</span>, respectively. As with all medications, efficacy results must be considered together with safety information to assess the potential benefit and risk for an individual patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c1fae872-b0fd-48a9-9592-f21f810595fd"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination With Metformin or Sulfonylurea</h2>
<p class="First">The addition of AVANDIA to either metformin or sulfonylurea resulted in significant reductions in <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> compared with either of these agents alone. These results are consistent with an additive effect on glycemic control when AVANDIA is used as combination therapy.</p>
<p><span class="Underline">Combination With Metformin:</span> A total of 670 patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in two 26-week, randomized, double-blind, placebo/active-controlled trials designed to assess the efficacy of AVANDIA in combination with metformin. AVANDIA, administered in either once-daily or twice-daily dosing regimens, was added to the therapy of patients who were inadequately controlled on a maximum dose (2.5Â grams/day) of metformin.</p>
<p>In one trial, patients inadequately controlled on 2.5Â grams/day of metformin (mean baseline FPG 216Â mg/dL and mean baseline HbA1c 8.8%) were randomized to receive 4Â mg of AVANDIA once daily, 8Â mg of AVANDIA once daily, or placebo in addition to metformin. A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of metformin and 4Â mg of AVANDIA once daily and 8Â mg of AVANDIA once daily, versus patients continued on metformin alone (Table 10).</p>
<a name="_RefID0EY1CI"></a><table width="100%">
<caption><span>Table 10. Glycemic Parameters in a 26-Week Combination Trial of AVANDIA Plus Metformin</span></caption>
<col width="45%">
<col width="11%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Metformin</span></p></td>
<td class="Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">4 mg Once Daily + Metformin</span></p>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">8 mg Once Daily + Metformin</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 113</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 116</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 110</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">214</p></td>
<td class="Rrule" align="center"><p class="First">215</p></td>
<td class="Rrule" align="center"><p class="First">220</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">-33</p></td>
<td class="Rrule" align="center"><p class="First">-48</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from metformin alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-40<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-53<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30 mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">45%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">61%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8.6</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">0.5</p></td>
<td class="Rrule" align="center"><p class="First">-0.6</p></td>
<td class="Rrule" align="center"><p class="First">-0.8</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from metformin alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-1.0<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-1.2<span class="Sup">a</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">45%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">52%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â <span class="Italics">P</span> &lt;0.0001 compared with metformin. </p>
<p>In a second 26-week trial, patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on 2.5Â grams/day of metformin who were randomized to receive the combination of AVANDIA 4Â mg twice daily and metformin (NÂ =Â 105) showed a statistically significant improvement in glycemic control with a mean treatment effect for FPG of -56Â mg/dL and a mean treatment effect for HbA1c of -0.8% over metformin alone. The combination of metformin and AVANDIA resulted in lower levels of FPG and HbA1c than either agent alone.</p>
<p>Patients who were inadequately controlled on a maximum dose (2.5Â grams/day) of metformin and who were switched to monotherapy with AVANDIA demonstrated loss of glycemic control, as evidenced by increases in FPG and HbA1c. In this group, increases in LDL and VLDL were also seen.</p>
<p><span class="Underline">Combination With a Sulfonylurea:</span> A total of 3,457Â patients with typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in ten 24- to 26-week randomized, double-blind, placebo/active-controlled trials and one 2-year double-blind, active-controlled trial in elderly patients designed to assess the efficacy and safety of AVANDIA in combination with a sulfonylurea. AVANDIA 2Â mg, 4Â mg, or 8Â mg daily was administered, either once daily (3 trials) or in divided doses twice daily (7Â trials), to patients inadequately controlled on a submaximal or maximal dose of sulfonylurea.</p>
<p>In these trials, the combination of AVANDIA 4Â mg or 8Â mg daily (administered as single- or twice-daily divided doses) and a sulfonylurea significantly reduced FPG and HbA1c compared with placebo plus sulfonylurea or further up-titration of the sulfonylurea. Table 11 shows pooled data for 8 trials in which AVANDIA added to sulfonylurea was compared with placebo plus sulfonylurea.</p>
<a name="_RefID0EJDDI"></a><table width="100%">
<caption><span>Table 11. Glycemic Parameters in 24- to 26-Week Combination Trials of AVANDIA Plus Sulfonylurea</span></caption>
<col width="36%">
<col width="13%">
<col width="19%">
<col width="13%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Twice-Daily Divided Dosing</span></p>
<p><span class="Bold">(5 Trials)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Sulfonylurea</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">2 mg Twice Daily + Sulfonylurea</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Sulfonylurea</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">4 mg Twice Daily + Sulfonylurea</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 397</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 497</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 248</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 346</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">204</p></td>
<td class="Rrule" align="center"><p class="First">198</p></td>
<td class="Rrule" align="center"><p class="First">188</p></td>
<td class="Rrule" align="center"><p class="First">187</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">11</p></td>
<td class="Rrule" align="center"><p class="First">-29</p></td>
<td class="Rrule" align="center"><p class="First">8</p></td>
<td class="Rrule" align="center"><p class="First">-43</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-42<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-53<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30Â mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">17%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">49%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">61%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">9.4</p></td>
<td class="Rrule" align="center"><p class="First">9.5</p></td>
<td class="Rrule" align="center"><p class="First">9.3</p></td>
<td class="Rrule" align="center"><p class="First">9.6</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">0.2</p></td>
<td class="Rrule" align="center"><p class="First">-1.0</p></td>
<td class="Rrule" align="center"><p class="First">0.0</p></td>
<td class="Rrule" align="center"><p class="First">-1.6</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-1.1<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-1.4<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">21%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">60%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">23%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">75%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Once-Daily Dosing</span></p>
<p><span class="Bold">(3 Trials)</span></p>
</td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Sulfonylurea</span></p></td>
<td class="Botrule Rrule" align="center">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">4 mg Once Daily + Sulfonylurea</span></p>
</td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Sulfonylurea</span></p></td>
<td class="Botrule Rrule" align="center">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">8 mg Once Daily + Sulfonylurea</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">N = 172</p></td>
<td class="Botrule Rrule" align="center"><p class="First">N = 172</p></td>
<td class="Botrule Rrule" align="center"><p class="First">N = 173</p></td>
<td class="Botrule Rrule" align="center"><p class="First">N = 176</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">198</p></td>
<td class="Rrule" align="center"><p class="First">206</p></td>
<td class="Rrule" align="center"><p class="First">188</p></td>
<td class="Rrule" align="center"><p class="First">192</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">17</p></td>
<td class="Rrule" align="center"><p class="First">-25</p></td>
<td class="Rrule" align="center"><p class="First">17</p></td>
<td class="Rrule" align="center"><p class="First">-43</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-47<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-66<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30 mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">17%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">48%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8.6</p></td>
<td class="Rrule" align="center"><p class="First">8.8</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
<td class="Rrule" align="center"><p class="First">8.9</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">0.4</p></td>
<td class="Rrule" align="center"><p class="First">-0.5</p></td>
<td class="Rrule" align="center"><p class="First">0.1</p></td>
<td class="Rrule" align="center"><p class="First">-1.2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea alone (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-0.9<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-1.4<span class="Sup">a</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">36%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">68%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â <span class="Italics">P</span> &lt;0.0001 compared with sulfonylurea alone. </p>
<p>One of the 24- to 26-week trials included patients who were inadequately controlled on maximal doses of glyburide and switched to 4Â mg of AVANDIA daily as monotherapy; in this group, loss of glycemic control was demonstrated, as evidenced by increases in FPG and HbA1c.</p>
<p>In a 2-year, double-blind trial, elderly patients (aged 59 to 89Â years) on half-maximal sulfonylurea (glipizide 10Â mg twice daily) were randomized to the addition of AVANDIA (nÂ =Â 115, 4Â mg once daily to 8Â mg as needed) or to continued up-titration of glipizide (nÂ =Â 110), to a maximum of 20Â mg twice daily. Mean baseline FPG and HbA1c were 157 mg/dL and 7.72%, respectively, for the arm receiving AVANDIA plus glipizide and 159 mg/dL and 7.65%, respectively, for the glipizide up-titration arm. Loss of glycemic control (FPG â‰¥180Â mg/dL) occurred in a significantly lower proportion of patients (2%) on AVANDIA plus glipizide compared with patients in the glipizide up-titration arm (28.7%). About 78% of the patients on combination therapy completed the 2Â years of therapy while only 51% completed on glipizide monotherapy. The effect of combination therapy on FPG and HbA1c was durable over the 2-year trial period, with patients achieving a mean of 132 mg/dL for FPG and a mean of 6.98% for HbA1c compared with no change on the glipizide arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a1947107-9123-4367-ab77-79f85b8109c2"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Combination With Sulfonylurea Plus Metformin</h2>
<p class="First">In two 24- to 26-week, double-blind, placebo-controlled trials designed to assess the efficacy and safety of AVANDIA in combination with sulfonylurea plus metformin, AVANDIA 4Â mg or 8Â mg daily, was administered in divided doses twice daily, to patients inadequately controlled on submaximal (10Â mg) and maximal (20Â mg) doses of glyburide and maximal dose of metformin (2Â g/day). A statistically significant improvement in FPG and HbA1c was observed in patients treated with the combinations of sulfonylurea plus metformin and 4Â mg of AVANDIA and 8Â mg of AVANDIA versus patients continued on sulfonylurea plus metformin, as shown in Table 12.</p>
<a name="_RefID0E6XDI"></a><table width="100%">
<caption><span>Table 12. Glycemic Parameters in a 26-Week Combination Trial of AVANDIA Plus Sulfonylurea and Metformin</span></caption>
<col width="38%">
<col width="17%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Sulfonylurea + Metformin</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">2 mg Twice Daily + Sulfonylurea + Metformin</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">AVANDIA</span></p>
<p><span class="Bold">4 mg Twice Daily + Sulfonylurea + Metformin</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 273</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 276</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">N = 277</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">189</p></td>
<td class="Rrule" align="center"><p class="First">190</p></td>
<td class="Rrule" align="center"><p class="First">192</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">14</p></td>
<td class="Rrule" align="center"><p class="First">-19</p></td>
<td class="Rrule" align="center"><p class="First">-40</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea plus metformin (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-30<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-52<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥30 mg/dL decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">46%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">62%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">8.7</p></td>
<td class="Rrule" align="center"><p class="First">8.6</p></td>
<td class="Rrule" align="center"><p class="First">8.7</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Change from baseline (mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">0.2</p></td>
<td class="Rrule" align="center"><p class="First">-0.4</p></td>
<td class="Rrule" align="center"><p class="First">-0.9</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	Difference from sulfonylurea plus metformin (adjusted mean)</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">â€“</p></td>
<td class="Rrule" align="center"><p class="First">-0.6<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">-1.1<span class="Sup">a</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>	% of patients with â‰¥0.7% decrease from baseline</dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">39%</p></td>
<td class="Botrule Rrule" align="center"><p class="First">63%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Â Â Â <span class="Italics">P</span> &lt;0.0001 compared with placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_589e7538-db77-4e19-b3fe-d53db016a2e8"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Park JY, Kim KA, Kang MH, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. <span class="Italics">Clin Pharmacol Ther</span> 2004;75:157-162.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_79912e06-53d8-46b2-b314-9e856438f993"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"> Each pentagonal film-coated TILTAB tablet contains rosiglitazone as the maleate as follows: 2 mgâ€“pink, debossed with GSK on one side and 2 on the other; 4 mgâ€“orange, debossed with GSK on one side and 4 on the other; 8 mgâ€“red-brown, debossed with GSK on one side and 8 on the other.</p>
<p>2 mg bottles of 60: NDC 0173-0861-18</p>
<p>4 mg bottles of 30: NDC 0173-0863-13</p>
<p>8 mg bottles of 30: NDC 0173-0864-13</p>
<p> Store at 25Â°C (77Â°F); excursions 15Â° to 30Â°C (59Â° to 86Â°F). Dispense in a tight, light-resistant container.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1d364acd-294e-47f4-88ed-400fc6c6a08a"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</span></p>
<p>There are multiple medications available to treat type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The benefits and risks of each available <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication should be taken into account when choosing a particular <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medication for a given patient.</p>
<p>Patients should be informed of the following:</p>
<dl>
<dt>â€¢</dt>
<dd>AVANDIA is not recommended for patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</dd>
<dt>â€¢</dt>
<dd>A meta-analysis of mostly short-term trials suggested an increased risk for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> with AVANDIA compared with placebo. Data from long-term clinical trials of AVANDIA versus other antidiabetes agents (metformin or sulfonylureas), including a cardiovascular outcome trial (RECORD), observed no difference in overall mortality or in major adverse cardiovascular events (MACE) and its components. </dd>
<dt>â€¢</dt>
<dd>AVANDIA is not recommended for patients who are taking insulin.</dd>
<dt>â€¢</dt>
<dd>Management of typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should include diet control. Caloric restriction, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and exercise are essential for the proper treatment of the diabetic patient because they help improve insulin sensitivity. This is important not only in the primary treatment of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, but in maintaining the efficacy of drug therapy.</dd>
<dt>â€¢</dt>
<dd>It is important to adhere to dietary instructions and to regularly have blood glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> tested. It can take 2Â weeks to see a reduction in blood glucose and 2 to 3Â months to see the full effect of AVANDIA.</dd>
<dt>â€¢</dt>
<dd>Blood will be drawn to check their liver function prior to the start of therapy and periodically thereafter per the clinical judgment of the healthcare professional. Patients with unexplained symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or dark urine should immediately report these symptoms to their physician.</dd>
<dt>â€¢</dt>
<dd>Patients who experience an unusually rapid increase in weight or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or who develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or other symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while on AVANDIA should immediately report these symptoms to their physician.</dd>
<dt>â€¢</dt>
<dd>AVANDIA can be taken with or without meals.</dd>
<dt>â€¢</dt>
<dd>When using AVANDIA in combination with other hypoglycemic agents, the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and their family members.</dd>
<dt>â€¢</dt>
<dd>Therapy with AVANDIA, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking AVANDIA. Thus, adequate contraception in premenopausal women should be recommended. This possible effect has not been specifically investigated in clinical trials so the frequency of this occurrence is not known.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f73b5f8-95cd-4cf9-9668-c16db9f5b55c"></a><a name="section-17"></a><p></p>
<p class="First">AVANDIA and TILTAB are registered trademarks of the GSK group of companies.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2014, the GSK group of companies. All rights reserved.</p>
<p>AVD:32PI</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_f025a556-e683-4409-bc36-3da2e900fedc"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">AVANDIA<span class="Sup">Â®</span> (ah-VAN-dee-a)</span></p>
<p><span class="Bold">(rosiglitazone maleate) tablets</span></p>
<p>Read this Medication Guide carefully before you start taking AVANDIA and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about AVANDIA, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about AVANDIA?</span></p>
<p><span class="Bold">AVANDIA may cause serious side effects, including:</span></p>
<p><span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span></p>
<dl>
<dt>â€¢</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> may be higher in people who take AVANDIA with insulin. Most people who take insulin should not also take AVANDIA.</dd>
<dt>â€¢</dt>
<dd>AVANDIA can cause your body to keep extra fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), which leads to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Extra body fluid can make some heart problems worse or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough.</dd>
<dt>â€¢</dt>
<dd>If you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, you cannot start AVANDIA.</dd>
<dt>â€¢</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), even if these symptoms are not severe, AVANDIA may not be right for you.</dd>
</dl>
<p>Call your doctor right away if you have any of the following:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, especially in the ankles or legs</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, especially when you lie down</dd>
<dt>â€¢</dt>
<dd>an unusually fast increase in weight</dd>
<dt>â€¢</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl>
<p>AVANDIA can have other serious side effects. Be sure to read the section below â€œWhat are possible side effects of AVANDIA?â€?</p>
<p><span class="Bold">What is AVANDIA?</span></p>
<p>AVANDIA is a prescription medicine used with diet and exercise to treat adults with type 2 (â€œadult-onsetâ€? or â€œnon-insulin dependentâ€?) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (â€œhigh blood sugarâ€?).</p>
<p>AVANDIA helps to control high blood sugar. AVANDIA may be used alone or with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. AVANDIA can help your body respond better to insulin made in your body. AVANDIA does not cause your body to make more insulin. </p>
<p>AVANDIA is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or to treat a condition called <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p>
<p>It is not known if AVANDIA is safe and effective in children younger than 18Â years old.</p>
<p><span class="Bold">Who should not take AVANDIA?</span></p>
<p>Many people with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should not start taking AVANDIA. See â€œWhat should I tell my doctor before taking AVANDIA?â€?</p>
<p><span class="Bold">Do not</span> take AVANDIA if you are allergic to rosiglitazone or any of the ingredients in AVANDIA. See the end of this leaflet for a complete list of ingredients in AVANDIA.</p>
<p>Symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with AVANDIA may include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, tongue, or throat</dd>
<dt>â€¢</dt>
<dd>problems with breathing or swallowing</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>â€¢</dt>
<dd>raised red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on your skin or in your mouth, nose, or eyes</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> or feeling dizzy</dd>
<dt>â€¢</dt>
<dd>very rapid heartbeat</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking AVANDIA?</span></p>
<p>Before starting AVANDIA, ask your doctor about what the choices are for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, and what the expected benefits and possible risks are for you in particular.</p>
<p>Before taking AVANDIA, tell your doctor about all of your medical conditions, including if you:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">have heart problems or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">have type 1 (â€œjuvenileâ€?) <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</span> These conditions should be treated with insulin.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">have a type of diabetic eye disease called <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span></span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the back of the eye).</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">have liver problems.</span> Your doctor should do blood tests to check your liver before you start taking AVANDIA and during treatment as needed.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">had liver problems while taking REZULIN<span class="Sup">â„¢</span> (troglitazone), another medicine for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant.</span> It is not known if AVANDIA can harm your unborn baby. You and your doctor should talk about the best way to control your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> during pregnancy. If you are a premenopausal woman (before the â€œchange of lifeâ€?) who does not have regular monthly periods, AVANDIA may increase your chances of becoming pregnant. Talk to your doctor about birth control choices while taking AVANDIA. Tell your doctor right away if you become pregnant while taking AVANDIA.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">are breastfeeding or planning to breastfeed.</span> It is not known if AVANDIA passes into breast milk. You and your doctor should decide if you will take AVANDIA or breastfeed. You should not do both.</dd>
</dl>
<p>Tell your doctor about all of the medicines you take including prescription and non-prescription medicines, vitamins or herbal supplements. AVANDIA and certain other medicines can affect each other and may lead to serious side effects including high or low blood sugar, or heart problems. Especially tell your doctor if you take:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">insulin.</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">any medicines for high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or for prevention of heart disease or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></dd>
</dl>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is alright to take AVANDIA with other medicines.</p>
<p><span class="Bold">How should I take AVANDIA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take AVANDIA exactly as prescribed. Your doctor will tell you how many tablets to take and how often. The usual daily starting dose is 4 mg a day taken one time each day or 2 mg taken two times each day. Your doctor may need to adjust your dose until your blood sugar is better controlled.</dd>
<dt>â€¢</dt>
<dd>AVANDIA may be prescribed alone or with other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines. This will depend on how well your blood sugar is controlled.</dd>
<dt>â€¢</dt>
<dd>Take AVANDIA with or without food.</dd>
<dt>â€¢</dt>
<dd>It can take 2 weeks for AVANDIA to start lowering blood sugar. It may take 2 to 3 months to see the full effect on your blood sugar level.</dd>
<dt>â€¢</dt>
<dd>If you miss a dose of AVANDIA, take it as soon as you remember, unless it is time to take your next dose. Take your next dose at the usual time. Do not take double doses to make up for a missed dose.</dd>
<dt>â€¢</dt>
<dd>If you take too much AVANDIA, call your doctor or poison control center right away.</dd>
<dt>â€¢</dt>
<dd>Test your blood sugar regularly as your doctor tells you.</dd>
<dt>â€¢</dt>
<dd>Diet and exercise can help your body use its blood sugar better. It is important to stay on your recommended diet, lose extra weight, and get regular exercise while taking AVANDIA.</dd>
<dt>â€¢</dt>
<dd>Your doctor should do blood tests to check your liver before you start AVANDIA and during treatment as needed. Your doctor should also do regular blood sugar tests (for example, â€œA1Câ€?) to monitor your response to AVANDIA.</dd>
</dl>
<p><span class="Bold">What are possible side effects of AVANDIA?</span></p>
<p><span class="Bold">AVANDIA may cause serious side effects including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span> See â€œWhat is the most important information I should know about AVANDIA?â€?</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span>.</span> AVANDIA may increase the risk of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Talk to your doctor about what this means to you.<br><span class="Bold">Symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> can include the following:</span><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> in the center of your chest that lasts for more than a few minutes, or that goes away or comes back</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> that feels like uncomfortable pressure, squeezing, fullness, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw, or stomach</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></dd>
<dt>â€¢</dt>
<dd>breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>feeling lightheaded</dd>
</dl>
</dd>
<dt>Â </dt>
<dd><span class="Bold">Call your doctor or go to the nearest hospital emergency room right away if you think you are having a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>).</span> AVANDIA can cause <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. See â€œWhat is the most important information I should know about AVANDIA?â€?</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>.</span> AVANDIA can cause <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> that may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or extra body fat. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> can be a serious problem for people with certain conditions including heart problems. See â€œWhat is the most important information I should know about AVANDIA?â€?</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Liver problems.</span> It is important for your liver to be working normally when you take AVANDIA. Your doctor should do blood tests to check your liver before you start taking AVANDIA and during treatment as needed. Call your doctor right away if you have unexplained symptoms such as:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
<dt>â€¢</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>â€¢</dt>
<dd>loss of appetite</dd>
<dt>â€¢</dt>
<dd>dark urine</dd>
<dt>â€¢</dt>
<dd>yellowing of your skin or the whites of your eyes.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span></span> (a diabetic eye disease with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye). Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly. Very rarely, some people have had vision changes due to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye while taking AVANDIA.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> (broken bones),</span> usually in the hand, upper arm, or foot. Talk to your doctor for advice on how to keep your bones healthy.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Low red blood cell count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>).</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span> or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> may mean that your blood sugar is too low. This can happen if you skip meals, if you use another medicine that lowers blood sugar, or if you have certain medical problems. Call your doctor if low blood sugar levels are a problem for you.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Ovulation</span> (release of egg from an ovary in a woman) leading to pregnancy. Ovulation may happen in premenopausal women who do not have regular monthly periods. This can increase the chance of pregnancy. See â€œWhat should I tell my doctor before taking AVANDIA?â€?</dd>
</dl>
<p>The most common side effects of AVANDIA reported in clinical trials included <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store AVANDIA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store AVANDIA at room temperature, 59Â°F to 86Â°F (15Â°C to 30Â°C). Keep AVANDIA in the container it comes in.</dd>
<dt>â€¢</dt>
<dd>Safely, throw away AVANDIA that is out of date or no longer needed.</dd>
<dt>â€¢</dt>
<dd>Keep AVANDIA and all medicines out of the reach of children.</dd>
</dl>
<p><span class="Bold">General information about AVANDIA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use AVANDIA for a condition for which it was not prescribed. Do not give AVANDIA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes important information about AVANDIA. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about AVANDIA that is written for healthcare professionals. You can also find out more about AVANDIA by calling 1-888-825-5249.</p>
<p><span class="Bold">What are the ingredients in AVANDIA?</span></p>
<p>Active Ingredient: rosiglitazone maleate.</p>
<p>Inactive Ingredients: hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide, triacetin, and 1 or more of the following: synthetic red and yellow iron oxides and talc.</p>
<p>Always check to make sure that the medicine you are taking is the correct one. AVANDIA tablets are triangles with rounded corners and look like this:</p>
<p>2 mg â€“ pink with â€œGSKâ€? on one side and â€œ2â€? on the other.</p>
<p>4 mg â€“ orange with â€œGSKâ€? on one side and â€œ4â€? on the other.</p>
<p>8 mg â€“ red-brown with â€œGSKâ€? on one side and â€œ8â€? on the other.</p>
<p>AVANDIA is a registered trademark of the GSK group of companies.</p>
<p>REZULIN is a trademark of its respective owner and is not a trademark of the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2014, the GSK group of companies. All rights reserved.</p>
<p>May 2014</p>
<p>AVD:8MG</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_56982421-9d35-4433-ad94-69131662bf31"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0834-18</span></p>
<p><span class="Bold">AVANDIA<span class="Sup">Â®</span></span></p>
<p><span class="Bold">ROSIGLITAZONE MALEATE TABLETS</span></p>
<p><span class="Bold">2 mg</span></p>
<p><span class="Bold">60 Tiltab<span class="Sup">Â®</span> Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 2 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 1/12</p>
<p>A100736</p>
<div class="Figure">
<a name="id13671477"></a><img alt="Avandia 2 mg 60 ct label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_3ccb076f-6811-4a18-903f-1ec9757bfba4"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0835-13</span></p>
<p><span class="Bold">AVANDIA<span class="Sup">Â®</span></span></p>
<p><span class="Bold">ROSIGLITAZONE MALEATE TABLETS</span></p>
<p><span class="Bold">4 mg</span></p>
<p><span class="Bold">30 Tiltab<span class="Sup">Â®</span> Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 4 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 1/12</p>
<p>A100737</p>
<div class="Figure">
<a name="id13670199"></a><img alt="Avandia 4 mg bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_3aecab00-81a2-41d7-bcfd-0a91090e0c68"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0836-13 </span></p>
<p><span class="Bold">AVANDIA<span class="Sup">Â®</span></span></p>
<p><span class="Bold">ROSIGLITAZONE MALEATE TABLETS</span></p>
<p><span class="Bold">8 mg</span></p>
<p><span class="Bold">30 Tiltab<span class="Sup">Â®</span> Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 8 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 1/12</p>
<p>A100738</p>
<div class="Figure">
<a name="id13668921"></a><img alt="Avandia 8 mg bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e8502a0a-7fbc-4a0b-8eee-5bef4e23621d"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0861-18</span></p>
<p><span class="Bold"><span class="Italics">AVANDIA<span class="Sup">Â®</span></span></span></p>
<p><span class="Bold"><span class="Italics">ROSIGLITAZONE MALEATE TABLETS</span></span></p>
<p><span class="Bold"><span class="Italics">2 mg</span></span></p>
<p><span class="Bold"><span class="Italics">60 Tiltab<span class="Sup">Â®</span> Tablets </span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 2 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 8/14</p>
<p>A127295</p>
<div class="Figure">
<a name="id7909192"></a><img alt="Avandia 2mg 60 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_cd27effc-964b-444e-ab3b-832a99a8edbd"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0863-13</span></p>
<p><span class="Bold"><span class="Italics">AVANDIA<span class="Sup">Â®</span></span></span></p>
<p><span class="Bold"><span class="Italics">ROSIGLITAZONE MALEATE TABLETS</span></span></p>
<p><span class="Bold"><span class="Italics">4 mg</span></span></p>
<p><span class="Bold"><span class="Italics">30 Tiltab<span class="Sup">Â®</span> Tablets </span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 4 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 8/14</p>
<p>A127296</p>
<div class="Figure">
<a name="id7909423"></a><img alt="Avandia 4mg 30 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_38362d12-7283-4f5c-a8cd-932012ebe8b4"></a><a name="section-24"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0173-0864-13 </span></p>
<p><span class="Bold"><span class="Italics">AVANDIA<span class="Sup">Â®</span></span></span></p>
<p><span class="Bold"><span class="Italics">ROSIGLITAZONE MALEATE TABLETS</span></span></p>
<p><span class="Bold"><span class="Italics">8 mg</span></span></p>
<p><span class="Bold"><span class="Italics">30 Tiltab<span class="Sup">Â®</span> Tablets </span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">Federal Law requires dispensing of AVANDIA<span class="Sup">Â®</span> with the Medication Guide provided with this bottle. </span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions 15<span class="Sup">o</span> â€“ 30<span class="Sup">o</span>C (59<span class="Sup">o</span> â€“ 86<span class="Sup">o</span>F). </p>
<p><span class="Bold">Do not use if printed safety seal under cap is broken or missing.</span></p>
<p>Each Tiltab<span class="Sup">Â®</span> tablet contains rosiglitazone maleate equivalent to 8 mg rosiglitazone. </p>
<p>Dispense in a tight, light-resistant container.</p>
<p><span class="Bold">Dosage:</span> See accompanying prescribing information.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 8/14</p>
<p>A127297</p>
<div class="Figure">
<a name="id7909644"></a><img alt="Avandia 8mg 30 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a&amp;name=avandia-spl-graphic-11.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0834</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0834-18</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">06/18/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">06/18/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0835</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0835-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">08/29/2015</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">08/29/2015</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0836</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red-brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0836-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">04/03/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem">04/03/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					2MG</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0861</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSK;2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0861-18</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					4MG</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0863</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSK;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0863-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVANDIAÂ 		
					8MG</strong><br><span class="contentTableReg">rosiglitazone maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0173-0864</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROSIGLITAZONE MALEATE</strong> (ROSIGLITAZONE) </td>
<td class="formItem">ROSIGLITAZONE</td>
<td class="formItem">8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red-brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSK;8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0173-0864-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021071</td>
<td class="formItem">05/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>GlaxoSmithKline LLC
							(167380711)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>39089037-eab4-4c52-922c-17eb69034aa7</div>
<div>Set id: ec682aec-e98f-41a1-9d21-eb7580ea3a8a</div>
<div>Version: 8</div>
<div>Effective Time: 20140507</div>
</div>
</div>Â <div class="DistributorName">GlaxoSmithKline LLC</div></p>
</body></html>
